All In Biotech

NDA 208294 · Astrazeneca

Bevespi Aerosphere

Formoterol Fumarate, Glycopyrrolate · Inhalation

Last checked: Nov 19, 2026Latest source record: Nov 5, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Apr 25, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

514

215 Phase 3, 21 recruiting

FAERS reports

1,968

799 serious, 233 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 24, 2023.

BEVESPI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: BEVESPI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions ( 5.1 , 5.2 )] . BEVESPI AEROSPHERE is a combination of glycopyrrolate, an anticholinergic, and formoterol fumarate, a long-acting beta 2 -adrenergic agonist (LABA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1 ) Limitations of Use : Not indicated for the relief of acute bronchospasm or for the treatment of asthma. ( 1 , 5.1 , 5.2 )

Mechanism: BEVESPI AEROSPHERE BEVESPI AEROSPHERE contains both glycopyrrolate and formoterol fumarate. The mechanism of action described below for the individual components applies to BEVESPI AEROSPHERE. These drugs represent two different classes of medications (an anticholinergic, and a long-acting selective beta 2 -adrenoceptor agonist) that have different effects on clinical physiology and inflammatory indices of COPD. Glycopyrrolate Glycopyrrolate is a long-acting antimuscarinic agent which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • BEVESPI AEROSPHERE · FORMOTEROL FUMARATE 0.0048MG/INH; GLYCOPYRROLATE 0.0090MG/INH · AEROSOL, METERED, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Formoterol" as an intervention, any sponsor and status, largest first.

All 514 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea378
  • death207
  • cough164
  • device malfunction161
  • chronic obstructive pulmonary disease156
  • off label use152
  • wrong technique in device usage process150
  • device issue145
  • product dose omission issue138
  • drug ineffective124
  • intentional product misuse118
  • wrong technique in product usage process113

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
20121
20152
20168
2017343
2018264
2019244
2020231
2021172
2022134
2023170
2024188
2025119
202691

Recalls

1 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bevespi Aerosphere (Glycopyrrolate/Formoterol Fum)

2024 spending

$65.5M

Beneficiaries

31,184

125,109 claims

Per beneficiary

$2,102

$38.54 per unit

View as table
YearSpending
2020$72,965,723
2021$77,583,374
2022$69,437,411
2023$66,814,262
2024$65,535,900

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,013 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.